Evidence map›Paper›PMID 21900534›Full record

ArticleClinical and vaccine immunology : CVI2011

Anti-gamma interferon antibodies enhance the immunogenicity of recombinant adenovirus vectors.

Shawn S Jackson, Jörn E Schmitz, Norman L Letvin

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Molecular mechanisms ofInfection and immunity · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Shawn S JacksonDivision of Viral Pathogenesis, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
Jörn E Schmitz
Norman L Letvin
Harvard University · USBeth Israel Deaconess Medical Center · US

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI BHARDWAJ, NINA · 2006 to 2011
$290.5M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Viral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI HAHN, BEATRICE H · 2005 to 2005
$14.9M
BINDING OF HIV PEPTIDES TO CLASS II MHC ON HUMAN CELLSR01AI030033 · NIAID · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI PERNIS, BENVENUTO G · 1990 to 1992
–
NIAID NIH HHS AI060354NIAID NIH HHS AI067854NIAID NIH HHS N01 AI030033NIAID NIH HHS N01-AI30033NIAID NIH HHS P30 AI060354NIAID NIH HHS U01 AI067854NIAID NIH HHS U19 AI067854
6 · The paper itself

Abstract

Vaccination for eliciting antigen-specific memory CD8(+) T cells may be facilitated by manipulating the pleiotropic effects of gamma interferon (IFN-γ). We assessed strategies for modulating the contribution of IFN-γ during the development of antigen-specific cytotoxic T lymphocyte (CTL) populations. We first showed that recombinant IFN-γ suppressed antigen expression in vitro from a recombinant adenovirus (rAd) vector in a dose-dependent manner and that addition of an anti-IFN-γ antibody (Ab) eliminated this suppression. Consistent with these in vitro findings, we found that HIV-1 envelope (Env)-specific CTL responses were higher in IFN-γ-knockout (GKO) mice than in wild-type mice following immunization with rAd. Since these observations suggested that IFN-γ might suppress rAd-induced CTL development, we assessed the ability of anti-IFN-γ Ab administration to augment rAd-elicited CTL in vivo. In fact, blockage of IFN-γ activity by monoclonal Ab administration was associated with elevated levels of interleukin 7 receptor alpha chain-positive (IL-7Rα(+)) Env-specific CTL populations postboost. These observations illustrate the utility of an anti-IFN-γ Ab for potentiating rAd immunizations to effect quantitative and qualitative changes in the effector and memory CTL populations.

Indexed as

AdenoviridaeAdjuvants, ImmunologicAIDS VaccinesAnimalsAntibodiesAntibodies, MonoclonalCD8-Positive T-Lymphocytesenv Gene Products, Human Immunodeficiency VirusFemaleGenetic VectorsHIV-1Interferon-gammaMiceMice, Inbred BALB CT-Lymphocytes, CytotoxicVaccines, SyntheticAdjuvants, ImmunologicAIDS VaccinesAntibodiesAntibodies, Monoclonalenv Gene Products, Human Immunodeficiency VirusInterferon-gammaVaccines, Synthetic

Identifiers

PMID21900534
PMCPMC3209036
OpenAlexW2168612563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.